Welcome to our dedicated page for Mersana Therapeutics SEC filings (Ticker: MRSN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a 250-page biotech filing packed with pharmacology terms, trial endpoints, and collaboration clauses can slow any analysis. Mersana Therapeutics SEC documents layer complex antibody-drug conjugate science on top of detailed R&D accounting—an ideal recipe for missed insights.
Stock Titan fixes that friction. Our AI-powered summaries translate every Mersana Therapeutics annual report 10-K simplified section, spotlighting Fleximer platform updates, cash runway disclosures, and key risk factors. Need the latest Mersana Therapeutics quarterly earnings report 10-Q filing? We post it the moment EDGAR releases, then surface revenue from partnerships, clinical-trial spend by program, and any changes to liquidity outlook—no manual page-flipping required.
Looking for insider sentiment? Receive real-time alerts whenever a director files Mersana Therapeutics insider trading Form 4 transactions. Our dashboard groups Mersana Therapeutics executive stock transactions Form 4 by buyer, price, and trial milestone so you can track conviction without spreadsheets.
- Rapid AI notes that flag 8-K material event triggers—perfect for "Mersana Therapeutics 8-K material events explained" searches.
- Side-by-side redline of sequential 10-Qs to answer "Mersana Therapeutics earnings report filing analysis."
- One-click access to the definitive proxy for "Mersana Therapeutics proxy statement executive compensation."
Whether you’re understanding Mersana Therapeutics SEC documents with AI for a quick model update or deep-diving into drug-candidate economics, Stock Titan delivers every filing type�10-K, 10-Q, 8-K, S-3, Form 4—along with plain-English context. Spend minutes, not evenings, turning dense ADC disclosures into actionable decisions.
Schonfeld Strategic Advisors LLC reported beneficial ownership of 5,673,852 shares of Mersana Therapeutics, Inc. (ticker MRSN), representing 4.55% of the company's common stock. The filing states Schonfeld has sole voting and sole dispositive power over all 5,673,852 shares and that these shares are held in accounts for clients, including separately managed accounts. The 4.55% figure is calculated using 124,631,339 shares outstanding as disclosed in Mersana's definitive proxy statement dated May 9, 2025. Schonfeld affirms the securities were acquired in the ordinary course of business and not to influence control of the issuer.
Mersana Therapeutics reported continued clinical progress on Emi-Le and XMT-2056 while facing clear financial strain. The company recorded a net loss of $24.3 million for the quarter and $48.4 million for the six months ended June 30, 2025, leaving an accumulated deficit of $944.0 million. Cash and cash equivalents declined to about $77.0 million at quarter end.
The report highlights encouraging interim Emi-Le activity, including a 31% confirmed ORR in B7-H4 high patients at intermediate doses and notable responses in adenoid cystic carcinoma and some TNBC and endometrial cohorts. The company also has meaningful collaboration balances, with deferred revenue around $98.6 million tied to GSK, Johnson & Johnson and Merck KGaA agreements. Management disclosed a strategic restructuring reducing headcount by ~55% and recorded $3.94 million of restructuring charges to focus resources on Emi-Le and select programs. The filing states there is substantial doubt about the company’s ability to continue as a going concern without additional financing.
Mersana Therapeutics announced a press release reporting business updates and financial results for the quarter ended June 30, 2025. The filing states the press release is furnished under Item 2.02 and that this furnished information, including Exhibit 99.1, is not to be deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other SEC filings except where specifically stated.
The Form 8-K lists Exhibit 99.1 (the press release) and Exhibit 104 (cover page interactive data) and is signed by the company’s Chief Financial Officer and Chief Operating Officer.
Mersana Therapeutics, Inc. (MRSN) has filed an 8-K disclosing that it will implement a 1-for-25 reverse stock split, effective 5:00 p.m. ET on 25 Jul 2025. Each block of 25 outstanding common shares will be reclassified into one share; fractional shares will be cashed out. The maneuver does not alter the company’s authorized share count or par value, but all equity incentive plan share pools and outstanding awards will be proportionally adjusted.
The reverse split is intended to restore compliance with Nasdaq’s $1.00 minimum bid price requirement, which the company previously flagged in its 2025 proxy. Post-split trading will commence on 28 Jul 2025 under the existing ticker “MRSN� with a new CUSIP of 59045L205.
No other material events, financial results or changes in fiscal year were reported. A copy of the Certificate of Amendment is attached as Exhibit 3.1.
FAQ
What is the current stock price of Mersana Therapeutics (MRSN)?
What is the market cap of Mersana Therapeutics (MRSN)?
